Like the moment in Succession when the family drama turns out to be a boardroom knife fight in expensive clothing, this paper starts as a review of drug-device regulation and then swerves into something bigger: medicine that can sense your body, make a decision, and adjust treatment on the fly.
The review by Wang and colleagues looks at "intelligent" drug-device combinations, or DDCs, which is a very formal way of saying your therapy is no longer just a pill, patch, or implant. It is a package deal. The drug, the hardware, the sensors, the software, and sometimes the wireless link all show up to work together, ideally without acting like a startup Slack channel at 2 a.m. (Wang et al., 2026).
From Dumb Hardware to Slightly Smarter Hardware
Old-school drug-device combos were things like drug-coated stents or basic infusion pumps. Useful, yes. Clever, sure. But mostly passive. They delivered medicine according to a preset plan, which is fine until your body decides to ignore the plan like Reviewer 2 ignoring your carefully written limitations section.
What makes the newer generation different is feedback. In control-system terms, a closed-loop system measures something, compares it to a target, and adjusts behavior accordingly. Cruise control for therapy, except the stakes are a bit higher than arriving five minutes late to brunch. In medical use, that might mean a sensor tracking glucose, inflammation, pressure, or drug concentration, while a pump, patch, or implant changes dosing in response.
That is the core shift Wang et al. describe: from passive delivery to adaptive, patient-specific treatment platforms built from biomaterials, nanotech, wireless communication, AI, and additive manufacturing. The paper also maps the regulatory headache across the United States, European Union, and China, because apparently building the cyborg medicine is only half the battle. The other half is paperwork.
The Best Proof So Far: Diabetes Did It First
If you want a real example of intelligent DDCs escaping the lab, diabetes is the obvious poster child. Commercial hybrid closed-loop insulin systems already combine a glucose sensor, control algorithm, and pump to automatically adjust insulin delivery. A 2023 systematic review found these systems improve time in range with low concern for severe hypoglycemia, which is the sort of sentence that sounds dry until you remember it means fewer dangerous highs and lows in actual daily life (Peacock et al., 2023).
The FDA's approval summary for the MiniMed 780G describes exactly this kind of loop: continuous glucose measurement plus automatic insulin adjustment for people with type 1 diabetes (FDA, 2023). So the idea is not science fiction. It is already clipped to belts and tucked into pockets.
But diabetes also shows the catch. When you connect sensing, dosing, software, batteries, and phone apps, you inherit new failure modes. In 2024, the FDA posted a Class I recall tied to Tandem's t:connect iOS app because a software problem could drain an insulin pump battery and suspend insulin delivery (FDA, 2024). Smart systems are helpful right up until Bluetooth decides to become the main character.
Why Researchers Are Excited Anyway
Meanwhile, wearable patches are getting more ambitious. A 2023 review of smart wearable patch systems describes platforms that combine biosensing with stimuli-responsive drug release for personalized care (Khadka et al., 2023). And in February 2026, a pilot clinical trial in Nature Biotechnology reported a wearable microneedle aptamer patch for continuous drug concentration measurement in humans, which starts to look a lot like the missing sensing half of future feedback-controlled dosing (Booth et al., 2026).
That last bit matters. If you cannot measure the right signal reliably, your "intelligent" device is just vibes with a battery.
The Awkward, Important Part
Wang et al. are refreshingly clear that this field still has homework. Sensors drift. Implants must stay biocompatible. Manufacturing gets messy when biology, electronics, and software all need to behave. Regulation gets even messier because agencies are no longer evaluating only a drug or only a device, but the entire ensemble cast and the chemistry between them. The FDA's 2023 guidance on physiologic closed-loop control makes that explicit, focusing on design, testing, animal studies, and labeling for these systems (FDA, 2023).
So no, this paper is not promising a robot pharmacist hidden in your smartwatch. It is more interesting than that. It is showing how medicine is inching toward therapies that listen before they act. Slow, regulated, clinically validated inching, yes. The kind of inching that takes five years, twelve supplemental figures, and one author who definitely missed a family wedding to finish the revisions. But still inching.
References
Wang Z, Zhou H, Liao R, Chen X, Zhang Q, Liu J, Zhang W, Shen Y. Advanced intelligent drug-device combination systems: regulatory landscapes, technological foundations, and clinical translation. Advanced Drug Delivery Reviews. 2026. DOI: 10.1016/j.addr.2026.115886. PubMed: PMID 42106080
Peacock S, Frizelle I, Hussain S. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Therapy. 2023;14(5):839-855. DOI: 10.1007/s13300-023-01394-5. PMCID: PMC10126177
Khadka B, Lee B, Kim KT. Drug Delivery Systems for Personal Healthcare by Smart Wearable Patch System. Biomolecules. 2023;13(6):929. DOI: 10.3390/biom13060929. PMCID: PMC10295889
Ghanim R, Kaushik A, Park J, Abramson A. Communication protocols integrating wearables, ingestibles, and implantables for closed-loop therapies. Device. 2023;1(4):100092. DOI: 10.1016/j.device.2023.100092
Cao et al. Smart closed-loop drug delivery systems. Nature Reviews Bioengineering. 2025. DOI: 10.1038/s44222-025-00328-z
Booth MA, Erdal MK, Larson M, et al. Pilot phase clinical trial of a wearable, electrochemical aptamer-based patch for continuous drug concentration measurement. Nature Biotechnology. Published February 4, 2026. DOI: 10.1038/s41587-026-03010-w
FDA. MiniMed 780G System - P160017/S091. Content current as of May 17, 2023. https://www.fda.gov/medical-devices/recently-approved-devices/minimed-780g-system-p160017s091
FDA. Technical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology. Final guidance, September 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-medical-devices-physiologic-closed-loop-control-technology
FDA. Tandem Diabetes Care recall of version 2.7 of the Apple iOS t:connect mobile app used with t:slim X2 insulin pump with Control-IQ technology. Updated August 2024. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/tandem-diabetes-care-inc-recalls-version-27-apple-ios-tconnect-mobile-app-used-conjunction-tslim-x2
Disclaimer: This blog post is a simplified summary of published research for educational purposes. The accompanying illustration is artistic and does not depict actual model architectures, data, or experimental results. Always refer to the original paper for technical details.